Topic: Leukemia and Lymphoma

Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost-effectiveness if priced between $143,900 to $273,700 per treatment cycle. Final Documents For questions or to request a Spanish translated Report-at-a-Glance or ICER […]

Interventions of Interest: tisagenlecleucel (KymriahTM , Novartis) axicabtagene ciloleucel (YescartaTM, Kite Pharma) ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. The policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit there will be changes needed in future pricing, payment, and […]